Marker Therapeutics Inc

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON, March 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the closing of an underwritten public offering of 32,282,857 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Marker from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $56.5 million.

Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock

HOUSTON, March 15, 2021 /PRNewswire/ --  Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:10 p.m.

Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference

Marker Therapeutics Inc (NASDAQ: MRKR) priced an underwritten public offering of 28.57 million common shares at $1.75 per share, representing a 31% discount from the last close price of $2.53 on Thursday.  The company will raise approximately $50 million in gross proceeds from the offering.

Marker Therapeutics Stock Plunges On Capital Raise At 31% Discount

HOUSTON, March 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the pricing of an underwritten public offering of 28,572,000 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Marker from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $50.0 million.

Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

HOUSTON, March 11, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Marker expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.

Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

HOUSTON, March 9, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2020.   "We are proud of our Company's continued progress, which has positioned us for a busy and productive year ahead," said Peter L.

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results

Hey Redditors, Redirect Your Attention To Marker

HOUSTON, Jan. 13, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today...

Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

Vivos Therapeutics

Tenet Healthcare

Cyclo Therapeutics, Inc.

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and sales of cyclodextrins (CD) and related products for food, pharmaceutical, and other industries to be used in diagnostics and specialty drugs with continuing growth in research and new product development.

Why Cyclo, Vivos Therapeutics And More Are Moving Today

HOUSTON, Jan. 5, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today...

Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q3 2020 Results - Earnings Call Transcript

HOUSTON, Nov. 9, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today...

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results

HOUSTON, Sept. 17, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.

Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

HOUSTON, Aug. 10, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.

Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results

HOUSTON, June 30, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today...

Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

HOUSTON, June 23, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced...

Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia

Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q1 2020 Results - Earnings Call Transcript

Babcock & Wilcox Enterprises

CynergisTek

Welbilt

Even in turbulent times, technical analysis helps pinpoint penny stocks that may be oversold and due for a positive trend reversal.

Penny Stocks to Buy Using Technical Analysis for May 2020

Terumo Corp

The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.

FDA grants emergency authorization to two blood purification systems

Marker Therapeutics' (MRKR) CEO Peter Hoang on Q3 2019 Results - Earnings Call Transcript

Marker reports positive positive preliminary results in a phase 1/2 study using MultiTTA to treat patients with pancreatic cancer.

Marker's Latest Pancreatic Cancer Data Points To Big Potential In Underserved Market

Marker Therapeutics' MultiTAA cell therapy has many advantages over other currently available therapies like CAR-T and TCR; most notable was the observation of epitope spreading which was an unexpected finding.

Marker Therapeutics: A Cell Therapy Biotech Thinking Outside Of The Box

As of late, it has definitely been a great time to be an investor Marker Therapeutics.

Will Marker Therapeutics Surge Higher?

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 7.69% and -100.00%, respectively, for the quarter ended March 2019.

MARKER THERAPEUTICS, INC. (MRKR) Reports Q1 Loss, Lags Revenue Estimates

An abstract detailing one of the company's clinical programs was rejected from an important industry meeting.

News for Marker Therapeutics Inc Stock (MRKR)